Edition:
United Kingdom

Novan Inc (NOVN.OQ)

NOVN.OQ on NASDAQ Stock Exchange Global Market

1.39USD
18 Jan 2019
Change (% chg)

$-0.13 (-8.55%)
Prev Close
$1.52
Open
$1.54
Day's High
$1.54
Day's Low
$1.38
Volume
28,087
Avg. Vol
17,705
52-wk High
$3.63
52-wk Low
$0.65

Summary

Name Age Since Current Position

Robert Ingram

75 2011 Independent Chairman of the Board

Paula Stafford

2019 President, Chief Operating Officer

G Kelly Martin

58 2017 Interim Chief Executive Officer, Director

Jeff Hunter

2018 Chief Business Officer, Interim Chief Financial Officer and Principal Financial Officer

Carri Geer

2019 Senior Vice President and Chief Technology Officer

Stanley Hollenbach

2017 Senior Vice President - Research and Development

Andrew Novak

36 2018 Vice President, Chief Accounting Officer and Principal Accounting Officer

Brian Johnson

50 2015 Chief Commercial Officer

Elizabeth Messersmith

2019 Chief Development Officer

Machelle Sanders

2017 Director

Eugene Sun

2018 Director

W. Geer

62 2015 Independent Director

Robert Keegan

70 2016 Independent Director

John Palmour

54 2010 Independent Director

Biographies

Name Description

Robert Ingram

Mr. Robert A. Ingram is a Independent Chairman of the Board of the Company. He is the Chairman of our board of directors and has served as a member of our board of directors since 2011. Since 2007, he has been a General Partner at Hatteras Venture Advisors III, LLC, a venture capital firm. Mr. Ingram currently serves on the board of directors of Valeant Pharmaceuticals International, Cree, Inc., Edwards Lifesciences Corporation, Regeneron Pharmaceuticals, Inc. and PhaseBio Pharmaceuticals, Inc.

Paula Stafford

Ms. Paula Brown Stafford is President, Chief Operating Officer of the company, she was a Chief Development Officer, Director of the company. Paula Brown Stafford has been promoted to President and the newly created role of Chief Operating Officer while remaining a member of the Board of Directors. Ms. Stafford joined Novan in March 2017 as Chief Development Officer. Under her direction, the Company has achieved several critical milestones with the completion of clinical trials in psoriasis, atopic dermatitis, and molluscum contagiousium over the course of 12 months. Prior to Novan, she was President of the Quintiles Global Clinical Development organization. Ms. Stafford will continue to report to G. Kelly Martin, Novan's Chief Executive Officer.

G Kelly Martin

Mr. G. Kelly Martin is Interim Chief Executive Officer, Director of the Company. He has served as a member of our board of directors since 2015. Since August 2015, Mr. Martin has served as the Chief Executive Officer of Malin Corporation PLC, a biotechnology company. Previously, he served as Chief Executive Officer of Elan Corporation PLC, a biotechnology company, from February 2003 to December 2013, and he founded Brandon Point Industries, a life sciences company, in January 2014, where he currently serves as director. Mr. Martin also currently serves on the board of directors of Viamet Pharmaceuticals Holdings, LLC.

Jeff Hunter

Mr. Jeff N. Hunter is no longer Chief Business Officer, Interim Chief Financial Officer and Principal Financial Officer of the Company effective February 8, 2019. Mr. Hunter has served as our Vice President of Technical Operations since 2006.

Carri Geer

Dr. Carri Geer is Senior Vice President and Chief Technology Officer of the company. Dr. Carri Geer has been promoted to Senior Vice President and Chief Technology Officer of Novan. Dr. Geer will be responsible for integrating formulation and analytical science with clinical translation in order to modify existing molecules and generate new chemical entity (NCE) opportunities. Dr. Geer has more than 10 years of industry experience both from her time at Novan and previously at Merck & Co., Inc. Dr. Geer has a Ph.D. in Chemistry from the University of North Carolina where she was a doctoral student and part of the Schoenfisch Lab, led by Novan co-founder.

Stanley Hollenbach

Mr. Stanley Hollenbach is Senior Vice President - Research and Development of the company. Prior to his promotion, Mr. Hollenbach led the design and execution of all pharmacology and toxicology testing for the Company as Vice President of Research and Nonclinical Development since joining Novan in March 2014. Mr. Hollenbach has more than 25 years of experience in the biotechnology industry, including lengthy terms of service at Genentech, COR Therapeutics, which was acquired by Millennium Pharmaceuticals, and Portola Pharmaceuticals. Most recently during his tenure at Portola, he focused primarily on platelet and fibrin mediated thrombosis, leading the preclinical development of orally bioavailable antiplatelet P2Y12 antagonists and the factor Xa inhibitors andexanet alpha and betrixaban. Mr. Hollenbach earned a Bachelor of Science in Microbiology and Bachelor of Arts in Chemistry from The University of North Carolina at Charlotte and a Juris Doctorate from the Peninsula University College of Law.

Andrew Novak

Mr. Andrew J. Novak is Vice President, Chief Accounting Officer and Principal Accounting Officer of the company. He has served as the Company’s Director of Financial Reporting and Analysis since June 2016 and Senior Director of Financial Reporting and Analysis since March 2018. From June 2014 until March 2016, Mr. Novak served as Director of Financial and SEC Reporting for Scynexis, Inc., a biotechnology company. Prior to joining Scynexis, Inc., Mr. Novak served as an Audit Manager at Deloitte & Touche from September 2005 to October 2012 and as a Technical Manager, Accounting & Audit Publications for the American Institute of Certified Public Accountants from October 2012 to June 2014. Mr. Novak is a certified public accountant and holds both a Bachelor of Science in Business Administration, Finance and a Master of Science in Accountancy from the University of North Carolina at Wilmington.

Brian Johnson

Mr. Brian Johnson is a Chief Commercial Officer of the Company. He has served as our Chief Commercial Officer since September 2015. Prior to joining Novan, Mr. Johnson worked at Galderma Laboratories, L.P. from 2003 to 2014, and most recently served as Vice President of Prescription Marketing and Chief Digital Officer. He also currently serves as principal and sole advisor of Two Hearts Group, LLC, a consulting company focused on drug development companies.

Elizabeth Messersmith

Dr. Elizabeth Messersmith is Chief Development Officer of the company. Dr. Elizabeth Messersmith, Senior Vice President, has been promoted to the role of Chief Development Officer with oversight of the clinical, medical, statistical, and regulatory activities of the Company. Dr. Messersmith, who joined Novan as Head of Clinical Operations in May 2018 from Quark Pharmaceuticals, has a Ph.D. in Neuroscience from the University of Texas Health Science Center at Houston. Dr. Messersmith has 25 years of hands-on drug development and biotechnology industry experience.

Machelle Sanders

Eugene Sun

W. Geer

Mr. W. Kent Geer is a Independent Director of the Company. He has served as a member of our board of directors since 2015. Mr. Geer was an audit partner with Ernst & Young LLP from 1989 to 2011. Beginning in 2012, Mr. Geer served as the Chairman of the board of directors of PowerSecure International, Inc. until the successful sale of the company in May 2016.

Robert Keegan

Mr. Robert J. Keegan is a Independent Director of the Company. He has served as a member of our board of directors since 2016. Mr. Keegan held the roles of Chief Executive Officer and Chairman of the board of directors of Goodyear Tire and Rubber Co. from 2000 to 2010. Most recently, he was an operating partner of the San Francisco-based private equity firm Friedman, Fleischer & Lowe. From 1972 to 2000, Mr. Keegan held various marketing, financial and managerial posts at Eastman Kodak, except for a two-year period from 1995 to 1997 when he worked as an Executive Vice President of the Avery Dennison Corporation. Mr. Keegan is Chairman of the Board of Loparex, Inc., serves on the boards of the Xerox Corporation.

John Palmour

Dr. John W. Palmour, Ph.D., is a Independent Director of the Company. He has served as a member of our board of directors since 2010. Since 1987, Dr. Palmour has worked at Cree, Inc., a company he co-founded and for which he currently serves as a Vice President and the Chief Technology Officer, Power & Radio Frequency.